Depreciation

EQS-News: adesso increases revenue by 26 % to EUR 1.14 billion / Sharp increase in personnel, fixed-price projects and lower licence income weigh down EBITDA in 2023 / Operating earnings set to rise again

Retrieved on: 
星期三, 四月 10, 2024

adesso increases revenue by 26 % to EUR 1.14 billion / Sharp increase in personnel, fixed-price projects and lower licence income weigh down EBITDA in 2023 / Operating earnings set to rise again

Key Points: 
  • adesso increases revenue by 26 % to EUR 1.14 billion / Sharp increase in personnel, fixed-price projects and lower licence income weigh down EBITDA in 2023 / Operating earnings set to rise again
    The issuer is solely responsible for the content of this announcement.
  • adesso increases revenue by 26 % to EUR 1.14 billion / Sharp increase in personnel, fixed-price projects and lower licence income weigh down EBITDA in 2023 / Operating earnings set to rise again in 2024
    In its consolidated financial statements, adesso SE has confirmed the preliminary figures for 2023 that were published by the end of February.
  • Supported by strong workforce growth, revenue increased by 26 %, topping EUR 1 billion for the first time, and adesso was able to further consolidate its own market position.
  • EUR 546.3 million of that figure was earned in the first half of 2023, and EUR 589.6 million followed in the second half.

EQS-News: DEAG fully on track with very good organic business development in 2023 – Detlef Kornett named sole CEO of DEAG

Retrieved on: 
星期三, 四月 10, 2024

EUR 31 million

Key Points: 
  • EUR 31 million
    Successful execution of buy-and-build strategy, set to remain integral to future growth
    Detlef Kornett appointed sole CEO effective April 2024 – DEAG founder Prof. Peter L.H.
  • The company's growth trajectory has been marked by sustained high profitability, resembling levels seen in the previous year.
  • DEAG is also reorganising its Executive Board: The company founder and CEO of DEAG, Prof. Peter L.H.
  • Schwenkow, CEO and founder of DEAG: “We are once again very pleased with our development in 2023.

EQS-News: Berentzen-Gruppe Aktiengesellschaft publishes 2023 Annual Report

Retrieved on: 
星期三, 四月 10, 2024

Revenue and earnings targets met in financial year 2023, forecast for 2024 announced

Key Points: 
  • Revenue and earnings targets met in financial year 2023, forecast for 2024 announced
    Consolidated revenues rise to EUR 185.7 million, consolidated EBIT comes to EUR 7.7 million
    Haselünne, March 28, 2024 – Berentzen-Gruppe Aktiengesellschaft, which is listed on the regulated market (General Standard) of the Frankfurt Stock Exchange (ISIN: DE0005201602), today published its Annual Report for the 2023 financial year.
  • “Despite the multiple crises that have impacted us all in the last few years, the Berentzen Group turned in a solid performance in financial year 2023”, said Oliver Schwegmann, CEO of Berentzen-Gruppe Aktiengesellschaft.
  • The Berentzen Group also announced its forecast for the 2024 financial year in the Annual Report 2023.
  • The 2023 Annual Report is published at: https://www.berentzen-gruppe.de/en/investors/reports

Invibes Advertising : Strong growth in annual results 2023.

Retrieved on: 
星期三, 四月 10, 2024

It should be noted that ML2Grow was sold in March 2024 and is therefore accounted for as a discontinued operation.

Key Points: 
  • It should be noted that ML2Grow was sold in March 2024 and is therefore accounted for as a discontinued operation.
  • The purpose of acquiring the company in 2019 was to strengthen Invibes' machine learning capabilities to further analyse data using AI.
  • Once again buoyed by a recovering digital advertising market, Invibes has entered 2024 with more favourable parameters.
  • In 2024, Invibes is confident that it will continue to grow its business while maintaining positive profitability.

BILENDI: Results for the 2023 financial year: marked improvement in profitability in the second half of 2023

Retrieved on: 
星期三, 四月 10, 2024

This performance is even more remarkable when we consider the 2 years of significant growth in 2021 and 2022, +29% and +39.5% respectively.

Key Points: 
  • This performance is even more remarkable when we consider the 2 years of significant growth in 2021 and 2022, +29% and +39.5% respectively.
  • Analysis by geographical area shows:
    Outside France (77% of sales), revenues increased by +1.2% (+2.1% at constant exchange rates) to €48.6m.
  • Adjusted operating profit and adjusted net profit group share rose by +11.5% and +10.0% respectively over the period, compared with the second half of 2022.
  • For the full year 2023, EBITDA was €11.4m, down -11.2% on the previous year, representing 18.2% of revenues.

ENOGIA: 2023 annual results

Retrieved on: 
星期三, 四月 10, 2024

The ORC Modules business generated revenue of €4.4 million in 2023, an increase of 42%.

Key Points: 
  • The ORC Modules business generated revenue of €4.4 million in 2023, an increase of 42%.
  • Among other significant ORC contract wins, the execution of the Company’s first order in the maritime sector, with Chantiers de l’Atlantique, began in the fourth quarter of 2023.
  • In addition, EBITDA for the second half of 2023 was at breakeven (positive €0.02 million), in line with the target announced in conjunction with the half-year results.
  • Net debt was €2.6 million at the close of the year, putting gearing at 32.6% as of 31 December 2023.

EQS-News: APONTIS PHARMA expects profitable growth again in 2024

Retrieved on: 
星期三, 四月 10, 2024

APONTIS PHARMA closed the 2023 financial year with a consolidated net loss of EUR 11.3 million (2022: consolidated net income of EUR 2.7 million).

Key Points: 
  • APONTIS PHARMA closed the 2023 financial year with a consolidated net loss of EUR 11.3 million (2022: consolidated net income of EUR 2.7 million).
  • Bruno Wohlschlegel, Chief Executive Officer of APONTIS PHARMA AG: “The 2023 financial year was characterized by significant changes for APONTIS PHARMA.
  • Following the successful implementation of the performance and efficiency improvement program earlier than planned, APONTIS PHARMA has laid the foundations for future profitable growth in Single Pill combinations.
  • As such, we launched our 15th Single Pill combination on the German market in March and continue to see considerable growth potential for Single Pill combinations from APONTIS PHARMA.

EQS-News: 2023 financial year: ElringKlinger records improved earnings and high nomination volume for e-mobility applications

Retrieved on: 
星期三, 四月 10, 2024

This will be driven in particular by the high volume of nominations that ElringKlinger received for e-mobility applications in 2023."

Key Points: 
  • This will be driven in particular by the high volume of nominations that ElringKlinger received for e-mobility applications in 2023."
  • In the financial year just ended, the Group managed to increase revenue by 2.7% to EUR 1,847.1 million (2022: EUR 1,798.4 million).
  • Thus, net income attributable to shareholders of ElringKlinger AG amounted to EUR 39.3 million in 2023 (2022: EUR -89.1 million).
  • This will be driven in particular by the high volume of nominations that ElringKlinger received for e-mobility applications in 2023."

EQS-News: United Internet with successful fiscal year 2023

Retrieved on: 
星期三, 四月 10, 2024

United Internet AG can look back on a successful fiscal year 2023.

Key Points: 
  • United Internet AG can look back on a successful fiscal year 2023.
  • Valuation effects from derivatives amounted to EUR -0.5 million in the prior-year period and EUR -6.3 million in the fiscal year 2023.
  • In an ad-hoc announcement on December 19, 2023, United Internet AG announced its guidance for the fiscal year 2024.
  • After concluding its fiscal year 2023, United Internet is now confirming this guidance and expects an increase in consolidated sales to approx.

EQS-News: 1&1 with successful fiscal year 2023

Retrieved on: 
星期三, 四月 10, 2024

Revenue rose in 2023 by 3.4 percent to €4,096.7 million (2022: €3,963.7 million).

Key Points: 
  • Revenue rose in 2023 by 3.4 percent to €4,096.7 million (2022: €3,963.7 million).
  • EBITDA 2023 (earnings before interest, taxes, depreciation and amortisation) at €653.8 million (2022: €693.3) is in line with the company's forecast.
  • EBIT amounted to €455.8 million (2022: €534.9 million) in 2023, as expected 14.8 percent below previous year's figure.
  • Assuming 176.3 million shares entitled to dividend (as per 31/12/2022), this would result in a total disbursement of €8.8 million for fiscal 2022.